Last reviewed · How we verify
NCT06229665
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
Phase 2, PHASE3 trial testing Valeda Light Delivery System in Dry Age-related Macular Degeneration in 75 participants. Participants enrolled and being followed up; not accepting new ones.
1 May 2025
Quick facts
| Lead sponsor | LumiThera, Inc. |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 25 October 2023 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Valeda Light Delivery System
Conditions studied
- Dry Age-related Macular Degeneration — all drugs for Dry Age-related Macular Degeneration →
Sponsor
LumiThera, Inc.
Who can join
50 and older, any sex, with Dry Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06229665
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT06536062 — Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma. · NA · recruiting
- NCT05797896 — Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study · active not recruiting
- NCT05706896 — Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Pla · NA · recruiting
- NCT04627428 — Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular · Phase 1, PHASE2 · recruiting
- NCT04065490 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) · NA · active not recruiting
Other LumiThera, Inc. trials
Trials by the same sponsor.
- NCT04522999 — Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration · NA · completed
- NCT04065490 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III) · NA · active not recruiting
- NCT03878420 — Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06229665 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LumiThera, Inc.
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06229665.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing